what is a glp-1 agonist medication Medications for Weight Loss Holding GLP-1 Agonists Prior to

Mediators of inflammation

Suction was applied and supplemental oxygen given

JAMA (2022) 327:138

Indication 20.3.6

5 As comparison, 70/30 mixed insulin aspart was shown to have a mean increased weight of 4.04 kg

The opportunities in these indications can be assessed by deploying effective new product planning / opportunity assessment methodologies, including evaluating the following for each potential indication: Level of in-class / competitive activity Likelihood of technical and regulatory success (i.e., based on scientific rationale and regulatory precedent) Level and nature of unmet needs for new therapies in the disease area of interest Potential for GLP1-s to address these unmet needs Commercial attractiveness of market Potential speed to market Alignment with individual manufacturer portfolio / strategy / capabilities Conclusion Incretin mimetics have had an immense and growing impact on patient outcomes